IN2012CH03125A - - Google Patents

Download PDF

Info

Publication number
IN2012CH03125A
IN2012CH03125A IN3125CH2012A IN2012CH03125A IN 2012CH03125 A IN2012CH03125 A IN 2012CH03125A IN 3125CH2012 A IN3125CH2012 A IN 3125CH2012A IN 2012CH03125 A IN2012CH03125 A IN 2012CH03125A
Authority
IN
India
Prior art keywords
febuxostat
pharmaceutical composition
pharmaceutically acceptable
acceptable salt
bioavailability
Prior art date
Application number
Other languages
English (en)
Inventor
Allada Ramesh
Chandra Illapakurthy Dr Ashok
S Rudraraju Dr Varma
Patra Srikanta
Original Assignee
Aizant Drug Res Solutions Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aizant Drug Res Solutions Private Ltd filed Critical Aizant Drug Res Solutions Private Ltd
Priority to IN3125CH2012 priority Critical patent/IN2012CH03125A/en
Publication of IN2012CH03125A publication Critical patent/IN2012CH03125A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN3125CH2012 2012-07-31 2012-07-31 IN2012CH03125A (enrdf_load_stackoverflow)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN3125CH2012 IN2012CH03125A (enrdf_load_stackoverflow) 2012-07-31 2012-07-31

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3125CH2012 IN2012CH03125A (enrdf_load_stackoverflow) 2012-07-31 2012-07-31

Publications (1)

Publication Number Publication Date
IN2012CH03125A true IN2012CH03125A (enrdf_load_stackoverflow) 2015-07-03

Family

ID=54397191

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3125CH2012 IN2012CH03125A (enrdf_load_stackoverflow) 2012-07-31 2012-07-31

Country Status (1)

Country Link
IN (1) IN2012CH03125A (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021099935A1 (en) * 2019-11-18 2021-05-27 Zycie Technolegal Llp Pharmaceutical formulations for managing uric acid content in human body

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021099935A1 (en) * 2019-11-18 2021-05-27 Zycie Technolegal Llp Pharmaceutical formulations for managing uric acid content in human body

Similar Documents

Publication Publication Date Title
IN2014KN00948A (enrdf_load_stackoverflow)
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
SG10201804817TA (en) Delayed release compositions of linaclotide
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
IL221680A (en) Crystalline Forms for Sodium Salt of 5-Amino-3,2-Dihydropathalazine-4,1-Deon
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
UA115357C2 (uk) Похідні піридин-4-ілу
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
MX2012001691A (es) Composiciones de linaclotida que se desintegran oralmente.
UA112764C2 (uk) Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок
MX2011011767A (es) Combinacion antitumoral que comprende ave8062 y sorafenib.
PH12015500395A1 (en) Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor
MD20140122A2 (ro) Procedee de producere a clorhidratului de anamorelin cu un conţinut controlat de clorură
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
IN2012CH03125A (enrdf_load_stackoverflow)
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
MX342465B (es) Metodos para tratar enfermedades hematologicas usando 6-ciclohexil-1-hidroxi-4-metil-2(1h)-piridona.
WO2013083226A8 (de) Porenarmes, wasserfreies natriumcarbonat
WO2011107921A3 (en) Modified release composition of milnacipran
PH12015500394A1 (en) Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate
MX346497B (es) Compuestos para la diferenciacion de celulas madre mejorada en hepatocitos.
IN2014DN07897A (enrdf_load_stackoverflow)